Olema Pharmaceuticals, Inc. - Common Stock (OLMA)
23.89
-0.21 (-0.87%)
NASDAQ · Last Trade: Feb 26th, 10:55 AM EST

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.
Via The Motley Fool · February 25, 2026

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.
Via The Motley Fool · February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.
Via The Motley Fool · February 25, 2026
Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by a "rising tide" effect in the breast cancer treatment market—top insiders have begun offloading significant portions of their
Via MarketMinute · January 9, 2026
Focused on therapies for women's cancers, this clinical-stage biotech reported a significant insider sale amid a year of sharp stock gains.
Via The Motley Fool · January 9, 2026
On Thursday, there are stocks with unusual volume. Let's take a look.
Via Chartmill · November 20, 2025
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Via The Motley Fool · November 20, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · November 20, 2025
Via Benzinga · November 20, 2025
Via Benzinga · November 20, 2025
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
Via The Motley Fool · November 20, 2025
Let's explore the current happenings on the US markets on Wednesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
Via Chartmill · November 19, 2025
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Via The Motley Fool · November 19, 2025
Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Via The Motley Fool · November 19, 2025
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · November 18, 2025
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Via The Motley Fool · November 18, 2025
Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · November 18, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · November 18, 2025
Via Benzinga · November 18, 2025
"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.
Via Benzinga · November 18, 2025
Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · November 18, 2025
Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.
Via Stocktwits · November 18, 2025
Via Benzinga · November 18, 2025
Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favorable safety profile.
Via Benzinga · November 18, 2025
Via Benzinga · November 18, 2025